Home
ARVN
ARVN News

Latest Arvinas Inc. (ARVN) News on November 17, 2025

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

GlobeNewswire

a month ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

MT Newswires

a month ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

GlobeNewswire

a month ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade

MT Newswires

5 months ago

Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

GlobeNewswire

5 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

MT Newswires

5 months ago

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires

5 months ago

Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

GlobeNewswire

5 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

GlobeNewswire

5 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

MT Newswires

5 months ago

Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

GlobeNewswire

6 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer

BioPharma Dive

6 months ago

Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer

Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?

Zacks

6 months ago

Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?

Arvinas to Present at Jefferies Global Healthcare Conference

GlobeNewswire

6 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

Pfizer and Arvinas gamble to shift breast cancer treatment paradigm

Clinical Trials Arena

6 months ago

Pfizer and Arvinas gamble to shift breast cancer treatment paradigm

MT Newswires

6 months ago

UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating

MT Newswires

6 months ago

Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating

MT Newswires

6 months ago

Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Simply Wall St.

6 months ago

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)

Insider Monkey

6 months ago

Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)

MT Newswires

7 months ago

TD Cowen Downgrades Arvinas to Hold From Buy

MT Newswires

7 months ago

Jefferies Downgrades Arvinas to Hold From Buy, Adjusts Price Target to $10 From $52

Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

GuruFocus.com

7 months ago

Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates

Zacks

7 months ago

Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates

MT Newswires

7 months ago

Top Premarket Decliners

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

BioPharma Dive

7 months ago

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks

7 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

GlobeNewswire

7 months ago

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

GlobeNewswire

7 months ago

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

7 months ago

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

GlobeNewswire

7 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

Insider Monkey

7 months ago

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

Zacks

7 months ago

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

MT Newswires

7 months ago

Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Benzinga

7 months ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

Clinical Trials Arena

7 months ago

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

MT Newswires

7 months ago

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

GlobeNewswire

7 months ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Simply Wall St.

7 months ago

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire

8 months ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Zacks

8 months ago

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Insider Monkey

8 months ago

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Zacks

8 months ago

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Zacks

8 months ago

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Biotech Alert: Searches spiking for these stocks today

TipRanks

8 months ago

Biotech Alert: Searches spiking for these stocks today

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Zacks

8 months ago

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Zacks

8 months ago

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Zacks

8 months ago

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

MT Newswires

8 months ago

Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70

MT Newswires

8 months ago

Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

Zacks

8 months ago

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

MT Newswires

8 months ago

Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

Investor's Business Daily

8 months ago

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

MT Newswires

8 months ago

Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating

MT Newswires

8 months ago

Top Midday Decliners

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

Clinical Trials Arena

8 months ago

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

MT Newswires

8 months ago

Oppenheimer Downgrades Arvinas to Perform From Outperform

MT Newswires

8 months ago

Sector Update: Health Care

MT Newswires

8 months ago

Arvinas, Pfizer Say Vepdegestrant Trial Meets Primary Endpoint in Breast Cancer With ESR1 Mutations

MT Newswires

8 months ago

Top Premarket Decliners

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

GlobeNewswire

8 months ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Arvinas to Participate in Upcoming Investor Conferences

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

Zacks

8 months ago

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

MT Newswires

9 months ago

Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

Simply Wall St.

9 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

Zacks

9 months ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

Zacks

9 months ago

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

MT Newswires

9 months ago

Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Arvinas Inc Earnings Call

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

GuruFocus.com

9 months ago

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Zacks

9 months ago

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

MT Newswires

9 months ago

Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

GuruFocus.com

9 months ago

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

GlobeNewswire

9 months ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Motley Fool

10 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

MT Newswires

10 months ago

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

GlobeNewswire

10 months ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Clinical Trials Arena

a year ago

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

Benzinga

a year ago

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

MT Newswires

a year ago

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey

a year ago

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

a year ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

a year ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Insider Monkey

a year ago

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Arvinas Third Quarter 2024 Earnings: Beats Expectations

MT Newswires

a year ago

UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

GuruFocus.com

a year ago

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

MT Newswires

a year ago

Arvinas' Q3 Net Loss Narrows, Revenue Rises

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a year ago

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

a year ago

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Insider Monkey

a year ago

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

GlobeNewswire

a year ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

GlobeNewswire

a year ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Share on Social Networks: